Content of the article
Evolve’s manufacturing facility will be located in Texas and will be the first in the world to use PlasmaCap EBA® technology in the commercial scale production of plasma-derived therapeutics
Innovative technology extracts plasma proteins more efficiently and at higher yields to improve the reliable long-term supply of critical plasma-derived therapeutics
MISSISSAUGA, Ontario — Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, announced today that it has selected DPR Construction to act as general contractor for the construction of its new state-of-the-art commercial facility. be built in one of several recently shortlisted locations in Texas. This new facility, which is expected to open this summer, will produce plasma-derived therapeutics, initially intravenous immunoglobulin (IVIG) and human serum albumin (HSA), using Evolve’s innovative and proprietary PlasmaCap technology. EBA.
Content of the article
“Evolve continued to accelerate its business plan following significant progress in the clinical development of its lead product candidate, PlasmaCap IG (immunoglobulin intravenous, or IVIg), including the recent success of our Phase III clinical trial,” said Jim Caggiano, general manager. Officer at Evolve Biologics. “The selection of DPR to oversee the construction of our new commercial facility is another exciting step on the road to commercialization of our PlasmaCap EBA technology, which will begin in early 2024. In addition to securing a top notch general contractor, we are also well into a competitive process of selecting a site for our facility. We have limited the location to a small number of specific sites in Texas, all of which provide valuable synergies to our business, including a workforce “qualified work and access to major transport routes. We look forward to announcing the chosen location by June this year.”
Evolve has been partnering for some time with several leading architects, engineers, project managers, contractors and equipment suppliers, towards the construction of its first commercial facility, which will initially have the capacity to handle one million liters of plasma per year. , with a planned extension to two million liters. In addition to DPR, other key partners include Perkins & Will, a leading architectural firm, which led the completion of the design development; CRB, a leading engineering company that played a key role in the design and construction of the last plasma fractionation facility built in the United States; and CBRE, who have overseen project management for the installation project to date.
“We are both thrilled and honored to have been selected by Evolve Biologics to build their new plasma manufacturing facility in Texas,” said Jose Rivera, life sciences manager for DPR Construction in Texas. “As one of the largest life science contractors in the United States, DPR brings a wealth of experience from our dedicated team to many similar biopharma, manufacturing, CGMP, and facility projects. processing. This significant investment from Evolve Biologics will also be a very positive boost to our local economy here in Texas, supporting the state’s continued growth.
About PlasmaCap EBA®
PlasmaCap EBA is an innovative technology for efficient capture of plasma proteins in high yield and purity from human blood plasma. The technology uses proprietary affinity adsorbents in expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials without the use of precipitating solvents such as ethanol. Through substantial development efforts, PlasmaCap EBA has been able to demonstrate significant capture efficiencies for major therapeutic plasma proteins.
Content of the article
About Evolve Biologics® Inc.
Evolve Biologics Inc. is a leader in the development and commercialization of plasma-derived therapeutics, utilizing its proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these life-saving products. The Company is currently in the process of commercializing an exciting and innovative portfolio of product candidates, including IVIG (intravenous immunoglobulin) and albumin (human serum albumin), both of which are in advanced stages of regulatory approval in the United States. United States (FDA) and Canada. (Health Canada). The company is headquartered in Mississauga, Ontario, Canada. For more information, please visit: www.evolvebiologics.com.
Developing organic products ® and PlasmaCap EBA ® are registered trademarks of Evolve Biologics Inc.
Copyright © 2021
Jeffrey Mathews/Dan Gagnier